Foresight Diagnostics, which provides ultra-sensitive minimal residual disease (MRD) detection technology, today announced the launch of the PRECISE-HL clinical trial with the University of Washington ...

Niven Mehra presented results from the phase II INSPIRE trial, evaluating nivolumab 3mg/kg and ipilimumab 1mg/kg in molecularly selected mCRPC patients. The trial met its primary endpoint, with a ...

If a traditional CPAP machine isn't for you, you might consider the Inspire sleep apnea device as an alternative treatment option. Here's what you need to know. Taylor Leamey writes about all ...

“My goal, I guess, is to try and inspire as many of them, to give them the courage to try to do something.” It was her passion to inspire more women to get into sport that led her to her ...

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the ...

I-PREDICT matched McKeown with nivolumab, a checkpoint inhibitor approved for advanced melanoma, kidney cancer, and certain lung cancers but not for breast cancer. After two infusions, the tumor ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a decision expected by June 2025. The FDA accepted the supplemental biologics ...

An expert discusses how the updated results from CheckMate 274 (Galsky 2025) include updated disease-free survival (DFS) and interim overall survival (OS), along with other key end points such as ...

Click to share on Facebook (Opens in new window) Click to share on Twitter (Opens in new window) Click to share on Pinterest (Opens in new window) The world under our oceans is vastly unexplored.

Multiparametric quantitative MRI could potentially help differentiate between Duchenne muscular dystrophy and Becker muscular dystrophy early and improve the management of these conditions.